Facial trauma with life-threatening bleeding treated by andexanet alfa administration: A case report [PDF]
HeliyonRecently, anticoagulant reversal has become a treatment option for life-threatening bleeding, especially in intracranial hemorrhage. Although evidence of the beneficial efficacy of andexanet alfa accumulates in cases of intracranial hemorrhage, little is
Yasunori Shirakawa +6 more
doaj +5 more sources
Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland [PDF]
Swiss Medical Weekly, 2023 Anticoagulants are essential in preventing and treating thrombosis. Unfortunately, their use is accompanied by an enhanced risk of bleeding. Since the introduction of direct oral anticoagulants (DOACs), the risk of major bleeding has been reduced but ...
Anne Angelillo-Scherrer +5 more
doaj +3 more sources
Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study [PDF]
Western Journal of Emergency Medicine, 2023 Background: There are no randomized trials comparing andexanet alfa and 4 factor prothrombin complex concentrate (4F-PCC) for the treatment of factor Xa inhibitor (FXa-I)-associated bleeds, and observational studies lack important patient characteristics.
Adam J. Singer +7 more
doaj +2 more sources
Clinical and Applied Thrombosis/Hemostasis, 2020 Andexanet alfa is a recombinant factor Xa decoy protein, designed to reverse bleeding associated with oral anti-Xa agents. Andexanet alfa is also reported to neutralize the effects of heparin-related drugs.
Debra Hoppensteadt +2 more
exaly +2 more sources
Clinical and Applied Thrombosis/Hemostasis, 2021 The aim of this retrospective study was to compare andexanet alfa and 4-factor prothrombin complex (4F-PCC) for reversal of factor Xa (FXa)-inhibitor bleeding. Patients that received andexanet alfa for reversal were included.
exaly +2 more sources
Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model. [PDF]
PLoS ONE, 2018 Increasing use of factor Xa (FXa) inhibitors necessitates effective reversal agents to manage bleeding. Andexanet alfa, a novel modified recombinant human FXa, rapidly reverses the anticoagulation effects of direct and indirect FXa inhibitors.To evaluate
Genmin Lu +9 more
doaj +2 more sources
Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation.
Therapeutic Advances in Drug Safety, 2019 Background: Review of clinical data on andexanet alfa for the reversal of factor Xa (FXa) inhibitor associated anticoagulation. Data sources: In the present review, we identified articles via PubMed using the combined keywords andexanet alfa, apixaban ...
Elise Carpenter +2 more
exaly +2 more sources
Thirty‐day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life‐threatening direct oral anticoagulant‐related bleeding [PDF]
Journal of the American College of Emergency Physicians Open, 2022 Objective Compare 30‐day mortality among patients receiving the specific reversal agent andexanet alfa versus replacement prothrombin complex concentrate (PCC) in the management of direct‐acting oral anticoagulant (DOAC)–related bleeds.
Alexander T. Cohen +9 more
doaj +3 more sources
A meta‐analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor–related major bleeding [PDF]
Research and Practice in Thrombosis and Haemostasis, 2021 Background Andexanet alfa (andexanet) and prothrombin complex concentrate (PCC) are both reversal agents for major bleeding in patients using factor Xa inhibitors (FXaIs).
Tessa Jaspers +4 more
doaj +2 more sources
Use of Andexanet Alfa for Factor Xa Inhibitor Reversal in US Verified Trauma Centers: A National Survey [PDF]
Clinical and Applied Thrombosis/HemostasisDirect oral factor Xa inhibitors are replacing vitamin K-dependent antagonists as anticoagulation treatment in many clinical scenarios. Trauma centers are noting an increase in patients presenting on these medications.
Charles Fasanya MD, FRCS FACS +8 more
doaj +3 more sources